Answers are grounded in this paper and cite their sources.
Protein kinases coordinate cellular proliferation, differentiation, survival, metabolism, and stress responses, and dysregulated kinase signalingf is a defining feature of many malignancies. From 2021 through 2025, the U.S. Food and Drug Administration (U.S. FDA) approved 26 small-molecule kinase inhibitors for cancer therapy, extending precision treatment across non-small-cell lung cancer, hematologic malignancies, breast and ovarian cancers, cholangiocarcinoma, renal cell carcinoma, glioma, and other kinase-driven tumors. The approved agents illustrate advances in medicinal chemistry and translational pharmacology that include covalent inhibitors such as sotorasib and futibatinib, mutation-selective inhibitors such as taletrectinib and zongertinib, allosteric inhibitors such as asciminib and mirdametinib, and multitarget or combination strategies such as avutometinib plus defactinib. Improvements in central nervous system exposure, mutant selectivity, dosing durability, and biomarker-defined patient selection have broadened clinical utility. This Review integrates the discovery background, mechanism of action, synthetic route, pharmacological properties, clinical efficacy, safety, and regulatory context of these agents. It also evaluates acquired resistance, target-related and off-target toxicities, heterogeneous evidence supporting accelerated approvals, and the uncertain translation of biochemical potency into durable survival benefit. Successful kinase drug development therefore requires molecular design to be aligned with clinically achievable exposure, validated biomarkers, resistance surveillance, and confirmatory evidence.
No takes yet. Share an insight, caveat, or question.
Chen et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: